Despite major advances in genetic testing for breast cancer risk prediction, death rates remain disproportionately high among ...

"We hope our findings will help women better understand their risk of developing the disease across the course of life, so that they can make informed, individualized decisions about screening and ...

Clairity, Inc., a digital health innovator advancing AI-driven healthcare solutions, has received U.S. Food and Drug Administration (FDA) De Novo authorization for CLAIRITY BREAST, a novel, ...

Five scientific presentations to showcase the clinical impact of CLAIRITY BREAST across global screening programs Clairity’s first FDA authorized AI platform for breast cancer prediction demonstrates ...

Platform can help predict a woman's 5-year risk for developing breast cancer by analyzing routine mammograms. HealthDay News — The US Food and Drug Administration has granted de novo authorization to ...

An innovative biotech startup founded by researchers at Washington University School of Medicine in St. Louis has been acquired by Lunit, a leading company in developing AI-based technologies for ...

Areas of Uncertainty in Pancreatic Cancer Surveillance: A Survey Across the International Pancreatic Cancer Early Detection (PRECEDE) Consortium Breast and Ovarian Analysis of Disease Incidence and ...

n this study, 773 untreated breast cancer patients from all over China were collected and followed up for at least 5 years. We obtained clinical data from 773 cases, RNA sequencing data from 752 cases ...

Startup Clairity scored a green light from the FDA for the agency's first artificial intelligence tool designed to predict five-year breast cancer risk from a routine screening mammogram. According to ...

CLAIRITY BREAST provides clinicians with a first-in-class, novel platform for identifying future risk of breast cancer CLAIRITY BREAST analyzes subtle imaging features on screening mammograms that ...